Biogen (NASDAQ:BIIB) Upgraded to Overweight at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Biogen (NASDAQ:BIIB) from a neutral rating to an overweight rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $300.00 price objective on the biotechnology company’s stock, up from their previous price objective of $210.00.

Several other brokerages have also issued reports on BIIB. HC Wainwright upped their target price on Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Mizuho lifted their price target on shares of Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Wedbush lifted their price target on shares of Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, July 30th. UBS Group boosted their price objective on shares of Biogen from $240.00 to $270.00 and gave the stock a “buy” rating in a report on Friday. Finally, Canaccord Genuity Group upped their price objective on shares of Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $236.04.

Biogen Price Performance

BIIB opened at $229.41 on Monday. The stock has a 50-day moving average price of $217.96 and a 200-day moving average price of $202.72. Biogen has a 12-month low of $138.00 and a 12-month high of $238.24. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $33.90 billion, a P/E ratio of 40.60, a PEG ratio of 2.49 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company’s revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the company earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts predict that Biogen will post 12.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Biogen during the 2nd quarter valued at about $3,453,878,000. Primecap Management Co. CA purchased a new stake in Biogen in the 2nd quarter worth approximately $3,274,304,000. Legal & General Group Plc purchased a new stake in Biogen in the 2nd quarter worth approximately $322,640,000. Bank of America Corp DE purchased a new stake in Biogen in the 2nd quarter worth approximately $241,172,000. Finally, Deutsche Bank AG bought a new stake in shares of Biogen in the 2nd quarter worth approximately $193,165,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: J.P. Morgan said Biogen has an increasingly compelling catalyst path, highlighting potential 2027 data readouts for felzartamab in antibody-mediated rejection and litifilimab in cutaneous lupus erythematosus (CLE). The new target implies substantial upside from recent trading levels. JPMorgan Upgrades Biogen to Overweight From Neutral
• Positive Sentiment: Biogen’s 52-week Phase 2 AMETHYST data for litifilimab showed sustained improvements in skin disease activity among difficult-to-treat CLE patients, with a generally well-tolerated safety profile. The program also has FDA Breakthrough Therapy Designation, supporting its potential as a first-in-class, once-monthly treatment. What Biogen’s 52-Week Litifilimab CLE Data Means
• Positive Sentiment: Recent pipeline updates have strengthened the view that Biogen’s investment case is becoming less dependent on its Alzheimer’s franchise. The stock has also delivered strong recent performance, while one analysis characterized the shares as modestly undervalued despite that run. Biogen Could Be Undervalued After 52-Week Lupus Data
• Neutral Sentiment: Biogen is scheduled to report third-quarter 2026 results on October 28. The release could provide a near-term confirmation of operating trends and updated expectations ahead of the larger 2027 clinical catalysts.
• Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: several large investors, including FMR and JPMorgan, increased holdings, while VanEck, Point72 and T. Rowe Price reduced positions. This suggests improving interest but not uniform conviction.
• Negative Sentiment: Reported insider activity was limited but consisted of two sales and no purchases over the past six months. While not a major catalyst compared with the analyst upgrade, it provides a modest counterpoint to the bullish sentiment.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.